MeiraGTx Holdings PLC to Discuss Top-Line Data from the MGT009 Phase 1/2 Clinical Study of Botaretigene Sparoparvovec (AAV-RPGR) Transcript
Good morning. I'm Zandy Forbes, the President and CEO of MeiraGTx. Thank you for joining us today as we announce positive top line data from MGT009 Phase I/II clinical study, a botaretigene sparoparvovec for the treatment of patients suffering from X-linked retinitis pigmentosa with disease-causing variants in the eye-specific form of the RPGR gene.
Botaretigene sparoparvovec is an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa, which was previously called AAV-RPGR. And for the ease of presentation today, I'm just going to call it botaretigene.
Before we begin, please note that we will be making forward-looking statements as part of this presentation, which statements are subject to certain risks and uncertainties that may cause actual results, performance or achievements to materially differ from those forecasted. Specificity of these risks are described in our press release and most recent filings with the SEC.
I'm joined this morning by
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
